OOIR: Observatory of International Research

Papers

(The H4-Index of European Heart Journal-Cardiovascular Pharmacotherapy is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
The search for the holy grail: the balance between the risk of thrombosis and bleeding in patients	80
Early initiation of SGLT2 inhibitors after acute myocardial infarction	65
Interdisciplinary recommendations for recurrent hyperkalaemia: insights from the GUARDIAN-HK European Steering Committee	61
Sex-related differences in cardiovascular pharmacotherapy: fiction or fact? Why can’t we see the evidence?	57
Anticoagulation for the prevention of arterial thromboembolism in cancer patients by primary tumour site: a systematic review and meta-analysis of randomized trials	55
Associations of omega-3 fatty acids vs. fenofibrate with adverse cardiovascular outcomes in people with metabolic syndrome: propensity matched cohort study	45
Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: Scandinavian cohort study	41
Prognostic benefit of glucagon-like peptide-1 receptor agonists addition to sodium-glucose cotransporter 2 inhibitors in patients with atherosclerotic cardiovascular disease and heart failure: a cohor	40
Effects of renin–angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomized controlled trials	39
Finerenone for Diabetic Hearts: A Critical Appraisal of MACE Benefits and the Research Road Ahead	38
The role of aetiology in determining anticoagulation effectiveness for the treatment of Left Ventricular Thrombus	35
Current evidence and future perspective for the management of left-sided prosthetic valve thrombosis	32
Treatment with dual antiplatelet therapy after an acute coronary event may often be tailor-made for the patient	31
Net clinical benefit of extended dual pathway inhibition according to baseline risk in patients with chronic coronary syndrome: a COMPASS substudy	31
Edoxaban for 12 vs. 3 months in cancer-associated isolated distal deep vein thrombosis according to different doses: insights from the ONCO DVT study	31
Need for more evidence of safety in the pharmacological therapy of anaemia in chronic kidney disease: a cardiovascular perspective	30
Editorial on incidence and outcomes of transient new onset atrial fibrillation complicating acute coronary syndromes: results from a systematic review and meta-analysis	30
Impact of transfusion strategy on platelet aggregation and biomarkers in myocardial infarction patients with anemia	28
Flecainide to prevent atrial arrhythmia after patent foramen ovale closure, Rationale and design of the randomized AFLOAT study	28
Safety and efficacy of early initiation of sodium-glucose cotransporter-2 inhibitors after an acute coronary syndrome event: a meta-analysis of randomized controlled trials	27
Inhibition of interleukin-1 or -6 after myocardial infarction: pros, cons, and future perspectives	27
Efficacy and safety of P2Y12 inhibitor monotherapy after complex PCI: a collaborative systematic review and meta-analysis	26
Subcutaneous furosemide patch: heart failure decongestion ‘from the comfort of your home’	24
All about clinical trials	23
New ways of mitigating aldosterone in cardiorenal disease	23

Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy